Form 8-K - Current report:
SEC Accession No. 0000950170-24-124576
Filing Date
2024-11-12
Accepted
2024-11-12 07:31:36
Documents
12
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bbio-20241112.htm   iXBRL 8-K 44919
2 EX-99.1 bbio-ex99_1.htm EX-99.1 414438
  Complete submission text file 0000950170-24-124576.txt   602220

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT bbio-20241112.xsd EX-101.SCH 27258
14 EXTRACTED XBRL INSTANCE DOCUMENT bbio-20241112_htm.xml XML 4704
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 241443316
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)